Design to Dose: Integrating Quantitative Insights Across the Antibody Drug Conjugate ( ADC ) Development Lifecycle
Clinical and Translational Science · 2026-11 · 19 (11)
DOI: 10.1111/cts.70768 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 03.11.2026. Verfasst von Daniel Bending und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global PK/PD and Pharmacometrics, Eli Lilly and Company, Bracknell, UK. Hauptthemen laut MEDLINE: Immunoconjugates, Drug Development. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Antibody‐drug conjugates (ADCs) are among the most pharmacologically complex therapeutics in clinical development. Their behavior emerges from the interplay of antibody disposition, linker stability, payload pharmacology, and host physiology—interdependencies that render qualitative descriptors such as “stronger affinity” or “more potent payload” insufficient for reliable prediction of preclinical and clinical outcomes. Despite growing investment in quantitative medicine across drug development, no unified framework exists to guide quantitative decision‐making across the ADC design–development–dose‐optimization continuum. In this review we survey how fit‐for‐purpose quantitative approaches inform decisions at each stage of the development path, built on multi‐analyte data pipelines that capture the coupled pharmacokinetics (PK) of antibody, linker‐payload, and released payload. We highlight the utility of PBPK‐driven (physiologically‐based pharmacokinetics) feasibility and mechanistic sensitivity analyses for candidate triage and allometric and mechanism‐based translation for human exposure predictions. We also present a stepwise construction of exposure–response relationships bridging preclinical and clinical data and integration of efficacy and safety into a clinical utility index for dose optimization. Throughout, we argue that the central challenge for quantitative ADC development is not the absence of sophisticated models, but the disciplined integration of fit‐for‐purpose approaches into the decisions that shape the development path. We synthesize these ideas in the proposition of a preclinical clinical utility index (pCUI) as an efficacious lens for model‐informed ADC development: an integrative benefit–risk framework expanding on the established clinical utility index (CUI) that quantitatively assesses whether a therapeutic window plausibly exists before first‐in‐human dosing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global PK/PD and Pharmacometrics, Eli Lilly and Company, Bracknell, UK.
- PK Sciences, Translational Medicine, Novartis Biomedical Research, Cambridge, Massachusetts, USA.
- Clinical Pharmacology, Pharmacometrics, & Translational Sciences, MapLight Therapeutics, Inc., Redwood City, California, USA.
- Immunology Development, Novartis Pharmaceuticals UK Ltd, London, UK.
ORCID-Profile: Daniel Bending, Eshita Khera, Inez Lam, Innocent G Asiimwe, Venkatesh Pilla Reddy
Zitieren
APA
Bending, D., Khera, E., Lam, I., Asiimwe, I. G., & Pilla Reddy, V. (2026). Design to Dose: Integrating Quantitative Insights Across the Antibody Drug Conjugate ( ADC ) Development Lifecycle. Clinical and Translational Science, 19(11). https://doi.org/10.1111/cts.70768
Vancouver
Bending D, Khera E, Lam I, Asiimwe IG, Pilla Reddy V. Design to Dose: Integrating Quantitative Insights Across the Antibody Drug Conjugate ( ADC ) Development Lifecycle. Clinical and Translational Science. 2026;19(11). doi:10.1111/cts.70768
BibTeX
@article{Bending2026,
author = {Bending, Daniel and Khera, Eshita and Lam, Inez and Asiimwe, Innocent G and Pilla Reddy, Venkatesh},
title = {Design to Dose: Integrating Quantitative Insights Across the Antibody Drug Conjugate ( ADC ) Development Lifecycle},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {11},
doi = {10.1111/cts.70768}
}
EUVIMED